Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams

Background: Uropathogenic Escherichia coli are increasingly becoming resistant to flouroquinolones and to other commonly available antimicrobials. We sought to investigate the genetic basis for fluoroquinolone and extended spectrum beta-lactam (ESBL) resistance in 17 fluoroquinolone-resistant (MIC o...

Full description

Saved in:
Bibliographic Details
Main Authors: Samuel Kariuki, Gunturu Revathi, John Corkill, John Kiiru, Joyce Mwituria, Nazir Mirza, C. Anthony Hart
Format: Article
Language:English
Published: The Journal of Infection in Developing Countries 2007-12-01
Series:Journal of Infection in Developing Countries
Subjects:
Online Access:https://jidc.org/index.php/journal/article/view/361
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849323549811015680
author Samuel Kariuki
Gunturu Revathi
John Corkill
John Kiiru
Joyce Mwituria
Nazir Mirza
C. Anthony Hart
author_facet Samuel Kariuki
Gunturu Revathi
John Corkill
John Kiiru
Joyce Mwituria
Nazir Mirza
C. Anthony Hart
author_sort Samuel Kariuki
collection DOAJ
description Background: Uropathogenic Escherichia coli are increasingly becoming resistant to flouroquinolones and to other commonly available antimicrobials. We sought to investigate the genetic basis for fluoroquinolone and extended spectrum beta-lactam (ESBL) resistance in 17 fluoroquinolone-resistant (MIC of levofloxacin and ciprofloxacin >32 μg/ml) E. coli isolated from patients with urinary tract infections (UTIs). Methods: We applied PCR and Pulsed Field Gel Electrophoresis (PFGE) to characterize resistance genes and to determine clonal relatedness of strains, respectively. Results: Twelve of the 17 E. coli were resistant to multiple drugs, including ampicillin, co-amoxyclav, cefotaxime, ceftriaxone, ceftazidime and gentamicin and nalidixic acid and produced plasmid-mediated CTX-M-15 type ESBLs and CMY-2 AmpC type enzymes. The other 5 E. coli that were non-ESBL-producing were multiply resistant to ampicillin, nitrofurantoin, cefoxitin, nalidixic acid. Resistance to fluoroquinolones resulted from a combination of the presence of qnrA, qnrB, ciprofloxacin acetylating enzyme designated aac(6’)-1b-cr, and mutations in the two amino acid substitutions; 83 Serine (TCG) to Leucine (TTG) and 87 Aspartic acid (GAC) to Asparagine (AAC). Conclusion: Antibiogram patterns and PFGE of E. coli showed that these were community acquired UTI caused by pockets of clonally-related and some discreet strain types. Plasmid-mediated CTX-M-15 beta-lactamases and CMY-2 AmpC enzymes and fluoroquinolone resistant E. coli are becoming increasingly prevalent in hospitals in Kenya, posing a major challenge in the management of UTIs.
format Article
id doaj-art-8773d4fef80f46daa6bc662cc33da573
institution Kabale University
issn 1972-2680
language English
publishDate 2007-12-01
publisher The Journal of Infection in Developing Countries
record_format Article
series Journal of Infection in Developing Countries
spelling doaj-art-8773d4fef80f46daa6bc662cc33da5732025-08-20T03:48:58ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802007-12-0110310.3855/jidc.361Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactamsSamuel Kariuki0Gunturu Revathi1John Corkill2John Kiiru3Joyce Mwituria4Nazir Mirza5C. Anthony Hart6Centre for Microbiology Research, Kenya Medical Research Institute, PO Box 43640, NairobiDepartment of Pathology, Aga Khan University Hospital, P.O. Box 30270, NairobiDepartment of Medical Microbiology and Genito-Urinary Medicine, University of Liverpool, Liverpool, L69 3GACentre for Microbiology Research, Kenya Medical Research Institute, PO Box 43640, NairobiCentre for Microbiology Research, Kenya Medical Research Institute, PO Box 43640, NairobiThe Nairobi Hospital, PO Box 30026, NairobiDepartment of Medical Microbiology and Genito-Urinary Medicine, University of Liverpool, Liverpool, L69 3GABackground: Uropathogenic Escherichia coli are increasingly becoming resistant to flouroquinolones and to other commonly available antimicrobials. We sought to investigate the genetic basis for fluoroquinolone and extended spectrum beta-lactam (ESBL) resistance in 17 fluoroquinolone-resistant (MIC of levofloxacin and ciprofloxacin >32 μg/ml) E. coli isolated from patients with urinary tract infections (UTIs). Methods: We applied PCR and Pulsed Field Gel Electrophoresis (PFGE) to characterize resistance genes and to determine clonal relatedness of strains, respectively. Results: Twelve of the 17 E. coli were resistant to multiple drugs, including ampicillin, co-amoxyclav, cefotaxime, ceftriaxone, ceftazidime and gentamicin and nalidixic acid and produced plasmid-mediated CTX-M-15 type ESBLs and CMY-2 AmpC type enzymes. The other 5 E. coli that were non-ESBL-producing were multiply resistant to ampicillin, nitrofurantoin, cefoxitin, nalidixic acid. Resistance to fluoroquinolones resulted from a combination of the presence of qnrA, qnrB, ciprofloxacin acetylating enzyme designated aac(6’)-1b-cr, and mutations in the two amino acid substitutions; 83 Serine (TCG) to Leucine (TTG) and 87 Aspartic acid (GAC) to Asparagine (AAC). Conclusion: Antibiogram patterns and PFGE of E. coli showed that these were community acquired UTI caused by pockets of clonally-related and some discreet strain types. Plasmid-mediated CTX-M-15 beta-lactamases and CMY-2 AmpC enzymes and fluoroquinolone resistant E. coli are becoming increasingly prevalent in hospitals in Kenya, posing a major challenge in the management of UTIs.https://jidc.org/index.php/journal/article/view/361Fluoroquinolone-resistantESBL-producing MDR uropathogenic E. coliKenya
spellingShingle Samuel Kariuki
Gunturu Revathi
John Corkill
John Kiiru
Joyce Mwituria
Nazir Mirza
C. Anthony Hart
Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams
Journal of Infection in Developing Countries
Fluoroquinolone-resistant
ESBL-producing MDR uropathogenic E. coli
Kenya
title Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams
title_full Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams
title_fullStr Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams
title_full_unstemmed Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams
title_short Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams
title_sort escherichia coli from community acquired urinary tract infections resistant to fluoroquinolones and extended spectrum beta lactams
topic Fluoroquinolone-resistant
ESBL-producing MDR uropathogenic E. coli
Kenya
url https://jidc.org/index.php/journal/article/view/361
work_keys_str_mv AT samuelkariuki escherichiacolifromcommunityacquiredurinarytractinfectionsresistanttofluoroquinolonesandextendedspectrumbetalactams
AT guntururevathi escherichiacolifromcommunityacquiredurinarytractinfectionsresistanttofluoroquinolonesandextendedspectrumbetalactams
AT johncorkill escherichiacolifromcommunityacquiredurinarytractinfectionsresistanttofluoroquinolonesandextendedspectrumbetalactams
AT johnkiiru escherichiacolifromcommunityacquiredurinarytractinfectionsresistanttofluoroquinolonesandextendedspectrumbetalactams
AT joycemwituria escherichiacolifromcommunityacquiredurinarytractinfectionsresistanttofluoroquinolonesandextendedspectrumbetalactams
AT nazirmirza escherichiacolifromcommunityacquiredurinarytractinfectionsresistanttofluoroquinolonesandextendedspectrumbetalactams
AT canthonyhart escherichiacolifromcommunityacquiredurinarytractinfectionsresistanttofluoroquinolonesandextendedspectrumbetalactams